

# COMPARISON OF THREE DOSE CALCULATION METHODOLOGIES FOR 90-Y MICROSPPHERES RADIOEMBOLIZATION



## IPO PORTO

V. Antunes<sup>1,2</sup>, J.A.M. Santos,<sup>1,2,3</sup>



<sup>1</sup> Medical Physics, Radiobiology and Radiation Protection Group, Research Centre, Portuguese Institute of Oncology, Rua Bernardino de Almeida, 4200-072 Porto, Portugal

<sup>2</sup> Medical Physics Department, Portuguese Institute of Oncology, Rua Bernardino de Almeida, 4200-072 Porto, Portugal

<sup>3</sup> Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua J Viterbo Ferreira 228, 4050-313 Porto, Portugal

# INTRODUCTION

According to 2013/59/Euratom BSS, for all medical exposure of patients for radiotherapeutic purposes, including Nuclear Medicine, doses in target volumes shall be individually planned. Furthermore, doses to non-target volumes (e.g organs-at-risk) shall be as-low-as-reasonably-achievable and consistent with the intended radiotherapeutic purposes.

## PURPOSE

For  $^{90}\text{Y}$  microspheres radioembolization, three methods of activity calculation to be administered are usually used: empirical, body-surface-area (BSA) and partition methods. Accuracy and effectiveness of dose distribution calculation in the liver was compared using these three methods.

# METHODS

## EMPIRICAL MODEL

## BSA MODEL

## PARTITION MODEL

The % involvement by the tumor in the liver	Recomendes Y-90 dose (GBq)
< 25 %	2.0
25 % - 50 %	2.5
> 50 %	3.0

**BSA calculation**

$$BSA (m^2) = 0.20247 \times height (m)^{0.725} \times weight (kg)^{0.425}$$

**Activity**

$$A(GBq) = (BSA - 0.2) + \left( \frac{V_{tumour}}{V_{total\ liver}} \right)$$

$$Dose_{tissue} = \frac{49670(Gy / GBq / g) \times A_{total}(GBq)}{organ\ mass\ (g)}$$

$$Dose_{healthy\ liver} = \frac{49670 \times A_{total} \times \left( 1 - \frac{Lung\ shunt}{100} \right)}{V_{healthy\ liver} + \frac{T}{N} \times V_{tumour}}$$

$$Dose_{tumour} = \frac{T}{N} \times Dose_{healthy\ liver}$$


$$Dose_{lung} = \frac{49670 \times A_{total} \times \left( \frac{Lung\ shunt}{100} \right)}{V_{healthy\ liver} + \frac{T}{N} \times V_{tumour}}$$

The empirical model accepts the safety margins of the doses known from the previously published clinical data.


The BSA method varies <sup>90</sup>Y activity according to the patient's morphological characteristics (BSA - Body Surface Area) and the size of the tumor within the liver, calculated from CT images.

The partition model involves selecting safe radiation doses to the normal liver and lung. The radiation dose to the normal liver parenchyma should not exceed 80 Gy in normal liver and 70 Gy in cirrhotic liver. The dose to the lung should not exceed 25 Gy.

# METHODS



- Calculate the percentage shunted to the lungs.



- Determine the volumes of the normal liver and tumour from CT scan.

## BSA MODEL

- Determination of the injected activity.


## PARTITION MODEL

- Posterior calculation of the dose in total liver, healthy liver, tumour liver and lung.


# RESULTS

## <sup>99m</sup>Tc-MAA

## RADIOEMBOLIZATION



**Fig. 1:** The activity (~3.00 mCi) and dose (82.60 ± 38.11 Gy) in total liver determined from <sup>99m</sup>Tc-MAA biodistribution (surrogate of <sup>90</sup>Y).




**Fig. 2:** The activity (1.64 ± 0.49 GBq) and dose (43.24 ± 19.87 Gy) in total liver determined from <sup>90</sup>Y-Microsphere therapy.


# RESULTS

## <sup>99m</sup>Tc-MAA

## RADIOEMBOLIZATION



**Fig. 3:** The activity ( $1.26 \pm 0.62$  mCi) and dose ( $48.04 \pm 32.84$  Gy) in healthy liver determined from <sup>99m</sup>Tc-MAA biodistribution.




**Fig. 4:** The activity ( $0.80 \pm 0.43$  GBq) and dose ( $28.91 \pm 15.05$  Gy) in healthy liver determined from <sup>90</sup>Y-Microsphere therapy.


# RESULTS

## <sup>99m</sup>Tc-MAA

## RADIOEMBOLIZATION



**Fig. 5:** The activity ( $1.49 \pm 0.59$  mCi) and dose ( $364.96 \pm 295.59$  Gy) in tumour liver determined from <sup>99m</sup>Tc-MAA biodistribution.




**Fig. 6:** The activity ( $0.70 \pm 0.26$  GBq) and dose ( $193.64 \pm 215.20$  Gy) in tumour liver determined from <sup>90</sup>Y-Microsphere therapy.




# RESULTS

## <sup>99m</sup>Tc-MAA

## RADIOEMBOLIZATION



**Fig. 7:** The activity ( $0.25 \pm 0.14$  mCi) and dose ( $12.63 \pm 7.14$  Gy) in the lungs determined from <sup>99m</sup>Tc-MAA biodistribution.



**Fig. 8:** The activity ( $0.13 \pm 0.07$  GBq) and dose ( $6.70 \pm 3.72$  Gy) in the lungs liver determined from <sup>90</sup>Y-Microsphere therapy.


<sup>1</sup> Medical Physics, Radiobiology and Radiation Protection Group, Research Centre, Portuguese Institute of Oncology, Rua Bernardino de Almeida, 4200-072 Porto, Portugal

<sup>2</sup> Medical Physics Department, Portuguese Institute of Oncology, Rua Bernardino de Almeida, 4200-072 Porto, Portugal

<sup>3</sup> Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua J Viteiro Ferreira 228, 4050-313 Porto, Portugal

# CONCLUSIONS

## Difference between <sup>99m</sup>Tc-MAA and <sup>90</sup>Y-Microspheres dose calculation



The <sup>99m</sup>Tc-MAA is the pretreatment simulation for assessment of extra-hepatic depositions and lung shunting. The different physical properties, surgical procedures and timing between catheterizations results in MAA cause a discordance with microsphere distribution. The correlation between MAA and microsphere therapy dose calculation was performed for 15 patients.